Cross-Sector entity
Every one of those 1 sits in a single category, pharma. PreTRM Global is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention PreTRM Global, all published on March 19, 2026.
1 verified story tracked
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. PreTRM Global is most often covered alongside PRIME study, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention PreTRM Global, all published on March 19, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PreTRM Global. Shared-story counts are live from our verified record — not editorial picks.
Cash Runway Limit
Current capital projected to fund operations through this period across commercial milestones.
Commercial Target
Goal to reach 15-17 states and 5-7 live partner programs.
Q4 Earnings Call
Management confirms runway through 2028 and details PRIME study impact.
Fiscal Year End
Sera concludes 2025 with $95.8M in cash and a narrowed net loss.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
